Biosafety standards for working with Crimean-Congo hemorrhagic fever virus
Weidmann, Manfred and Avsic-Zupanc, Tatjana and Bino, Silvia and Bouloy, Michelle and Burt, Felicity and Chinikar, Sadegh and Christova, Iva and Dedushaj, Isuf and El-Sanousi, Ahmed and Elaldi, Nazif and Hewson, Roger and Hufert, Frank T. and Humolli, Isme and Jansen van Vuren, Petrus and Koçak Tufan, Zeliha and Korukluoglu, Gülay and Lyssen, Pieter and Mirazimi, Ali and Neyts, Johan and Niedrig, Matthias and Ozkul, Aykut and Papa, Anna and Paweska, Janusz and Sall, Amadou A. and Schmaljohn, Connie S. and Swanepoel, Robert and Uyar, Yavuz and Weber, Friedemann and Zeller, Herve,, 97, 2799-2808 (2016),
doi = https://doi.org/10.1099/jgv.0.000610,
publicationName = Microbiology Society,
issn = 0022-1317,
abstract= In countries from which Crimean-Congo haemorrhagic fever (CCHF) is absent, the causative virus, CCHF virus (CCHFV), is classified as a hazard group 4 agent and handled in containment level (CL)-4. In contrast, most endemic countries out of necessity have had to perform diagnostic tests under biosafety level (BSL)-2 or -3 conditions. In particular, Turkey and several of the Balkan countries have safely processed more than 100 000 samples over many years in BSL-2 laboratories. It is therefore advocated that biosafety requirements for CCHF diagnostic procedures should be revised, to allow the tests required to be performed under enhanced BSL-2 conditions with appropriate biosafety laboratory equipment and personal protective equipment used according to standardized protocols in the countries affected. Downgrading of CCHFV research work from CL-4, BSL-4 to CL-3, BSL-3 should also be considered.,
language=,
type=